期刊文献+

基于最新癌痛治疗指南分析住院患者癌痛用药规范性 被引量:6

Analysis of Drug Use Normalization in Inpatients with Cancer Pain Based on the Latest Cancer Pain Treatment Guidelines
下载PDF
导出
摘要 目的:调查住院患者癌痛用药情况,并与最新癌痛治疗指南进行对比,提高癌痛用药规范性。方法:采用回顾性调查方法,我院分析2014年10-12月住院癌症患者病历,调查患者疼痛发生率、镇痛药物使用情况,基于最新癌痛治疗指南对癌痛治疗药物评价合理性。结果:774例癌症患者中新发癌症的癌痛发生率为25.46%,癌痛患者中76.58%使用镇痛药物。按指南治疗方案,未使用过阿片类药物组(指南1组)与阿片类药物耐受组(指南2组)在联合用药方面差异无统计学意义,在镇痛药物选择和服药规律方面差异有统计学意义,羟考酮缓释片的使用上指南2组明显高于指南1组(P〈0.01),按时给药的比例指南2组也高于指南1组(P〈0.05);两组患者在癌痛评估和滴定上与指南存在差距,在具体镇痛药品使用上与指南不一致。结论:调查中发现的癌痛治疗方案与指南要求存在一定差距,需加强相关知识的宣教,推进癌痛的规范化治疗。 Objective:To investigate the therapeutic medication for inpatients with cancer pain, and compare with the latest cancer treatment guidelines to improve the rational drug use. Methods:By a retrospective study, the medical record analysis for the inpatients with cancer from October to December in 2014 was performed, and the incidence of pain and the therapeutic medication were investiga-ted and the rationality of drug use was evaluated based on the latest cancer pain treatment guidelines. Results:The incidence of cancer pain was 25. 46% of 774 cases with new cancer, and 76. 58% of the patients with cancer pain were treated with analgesic drugs. In ac-cordance with the guidelines for the treatment scheme, there was no significant difference between the Opioid-Naive group ( guide group 1) and the Opioids-Tolerant group (guide group 2) in the combination therapy, while there was significant difference in the drug selec-tion and the time of administration. In the guide group 1 the proportion of oxywdone controlled-release tablets was signiticantly higher than that in the guide group 2, the ratio of taking the medicine on time in the guide group 1 was also higher than that in the guide group 2. Both groups showed difference from the guidelines in the pain assessment and titration and specific analgesic drug use. Conclusion:The findings indicate the difference between the pain treatment and the guidelines in therapeutic medication of cancer pain, and the propaganda and education of relevant knowledge should be strengthened to promote the treatment standard.
作者 邵燕 李欣荣
出处 《中国药师》 CAS 2015年第11期1940-1943,共4页 China Pharmacist
关键词 癌痛 镇痛药物 合理用药 指南 Cancer pain Analgesic drugs Rational drug use Guidelines
  • 相关文献

参考文献10

二级参考文献31

  • 1徐建国,于世英.麻醉药品和精神药品规范化临床应用与管理[M].北京:人民卫生出版社,2007:10. 被引量:46
  • 2徐建国.疼痛药物治疗学[M].北京:人民卫生出版社,2007:264-275. 被引量:98
  • 3Messina J, Darwish M, Fine PG. Fentanyl buccal tablet [J]. Drugs Today, 2008,44 ( 1 ) : 41. 被引量:1
  • 4Zeppetella G, Ribeiro. Pharmacotherapy of cancer-related episodic pain[J]. Expert Opin Pharmacother, 2003,4 (4) : 493. 被引量:1
  • 5Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain[J]. Cancer, 2002,94(3) : 832. 被引量:1
  • 6Ashburn MA, Slevin KA, Messina J.The efficacy and safe- ty of fentanyl buccal tablet compared with immediate-rele- ae oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain[J]. Pain Med- icine, 2011,112(3) :693. 被引量:1
  • 7Zeppetella G.Breakthrough pain in cancer patients[J]. Clin- ical Ontology, 2011,23(6) : 393. 被引量:1
  • 8Tiseo P J, Thaler HT, Lapin J, et al. Morphine-6-glucuro- nide concentrations and opioid-related side effects: a sur-vey in cancer patients[J]. Pain, 1995,61 ( 1 ) : 47. 被引量:1
  • 9Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland[J]. Eur J Pain , 2009 ,13 ( 4 ) :331. 被引量:1
  • 10Darwish M, Kirby M, Robertson P J, et al. Absolute and relative bioavailability of femanyl buccal tablet and oral transmucosal fentanyl citrate[J]. Clin Pharmacol, 2007,47 (3):343. 被引量:1

共引文献208

同被引文献61

引证文献6

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部